Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Jeito Capital. (9/20/21). "Press Release: Jeito Capital Becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)". Paris.

Organisation Organisation Jeito I Fund
  Group Jeito Capital (Group)
Products Product Jeito I Fund
  Product 2 LIFE SCIENCES
Index terms Index term Jeito Capital–SEVERAL: investment, 202109 final closing Jeito I with addit €284m at €534m after €200m 1st close + €50m from Sanofi
  Index term 2 Jeito Capital–Sanofi: investment, 202011 investment €50m by Sanofi
Persons Person Tordjman, Rafaèle (Jeito Capital 201806– President + Founder before Sofinnova Partners 2001–2017)
  Person 2 Dandiguian, Sabine (Jeito Capital 202011 Managing Partner)
     


> Oversubscribed Jeito I becomes the largest European fund dedicated to the life sciences sector.

> Jeito Capital is dedicated to working with biotech entrepreneurs to provide financial and expert support in continuity to accelerate patients’ access to groundbreaking therapies.


Jeito Capital, a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at €534 million ($632 million), exceeding its original target of €500 million. Jeito I is the largest European fund dedicated to supporting companies in the life sciences sector.

Jeito Capital is building a strong and diversified portfolio of biotech and biopharma companies primarily based in Europe with global reach, focused on the treatment of life-threatening diseases. Jeito’s unique investment model provides support to entrepreneurs by a multi-talented team of experts integrated in the investment team across the entire drug development value chain, from translational science to market access, providing significant capital in continuity, up to €80 million ($100 million) in a single company.

Jeito I investments to date include French-based SparingVision and InnoSkel, in the fields of genomic ophthalmology and rare skeletal disorders, respectively, Dutch biotech Neogene Therapeutics in solid tumors, UK-based Pulmocide in severe respiratory diseases, and Swiss-French Alentis Therapeutics in fibrosis and related cancers.

Jeito I attracted leading global investors including the European Investment Fund (EIF), the American pension fund Teacher Retirement System of Texas (TRS), which has made its first-ever investment into a European fund dedicated to the biotech sector, and Temasek, a global investor headquartered in Singapore with deep experience investing in life sciences.

Founded and directed by Dr Rafaèle Tordjman, MD PhD, Jeito Capital was launched in January 2020 and completed a first funding round of €200 million with the strategic support of investors such as AXA, Aviva, the French public investment bank (BPI), the Caisse des Dépôts et des Consignations (CDC), CNP Assurances, Fortis BNP Paribas, Pro BTP, etc. In the following months Sanofi selected Jeito as its first ever investment into a private French-based fund, investing €50 million.

Rafaèle Tordjman, Founder and CEO of Jeito Capital, said: “We are extremely proud to have closed Jeito I, making it the largest European fund dedicated to the life sciences sector. We have thus exceeded our original target and have attracted a group of leading global investors, a testament to Jeito’s unique investment model and team. I am pleased to welcome new investors including the EIF, TRS and Temasek and would like to thank our existing investors for their unwavering support. This important achievement will enable Jeito to fulfill its mission: to provide continuous financial support and industry expertise to talented entrepreneurs to accelerate the development of revolutionary therapies and guaranteeing patients quicker access to medical innovations.”

Sabine Dandiguian, Managing Partner of Jeito Capital, added: “This exceptional fundraising success confirms Jeito’s investment model driven by Rafaèle Tordjman. I am very proud to be part of this multi-talented team which, thanks to its expertise across all stages of company development, is able to uncover and support the best scientific quality start-ups in Europe, with a global reach. Thanks to Jeito’s dynamic team we have already developed a pipeline of high-quality deal flow. We look forward to achieving our shared ambitions and making a significant and meaningful difference to patients’ lives.”


ENDS


About Jeito Capital

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please follow @Jeito_life on Twitter or LinkedIn.

   
Record changed: 2021-10-12

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Jeito Capital (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top